About
Ayuvant is developing a novel immunotherapy platform using RNA-nanoparticles to instruct the immune system to recognize and attack cancer cells, targeting patients who do not benefit from current immunotherapies.
Explore Ayuvant's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.